High discontinuation rates of GLP-1 agonists found among patients with obesity

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

Engineered NK cells with IL-21 show strong antitumor activity against glioblastoma

Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo,

August 12, 2024

New study shows XBB.1.5 COVID-19 vaccine significantly reduces hospitalizations and ICU admissions in older adults

Study evaluates the effectiveness of the XBB.1.5 COVID-19 vaccine in reducing hospitalizations and ICU admissions among vaccinated adults aged 60 and over in the Netherlands,

December 18, 2023

A Q&A with the global head of Boehringer Ingelheim’s innovation unit

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline. There was obesity and liver

October 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.